Oct 30 2010
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.
“Down regulation of β-catenin mRNA by a locked nucleic acid oligonucleotide antagonist inhibits tumor growth in experimental models of human cancer”
LNA Compound Poster Presentations
"Down-modulation of the androgen receptor with EZN-4176 inhibits the growth of prostate tumor and potentiates the inhibitory effect of MDV-3100, a novel anti-androgen," Yixian Zhang et al. Poster No. 218, November 17, 12:00 - 2:20 p.m. CEST
"Down regulation of β-catenin mRNA by a locked nucleic acid oligonucleotide antagonist inhibits tumor growth in experimental models of human cancer," Melissa Dumble et al. Poster No. 53, November 17, 12:00 - 2:20 p.m. CEST
"Reduced expression of HER3 with a specific RNA antagonist is associated with antitumor effects in preclinical models of cancer," Yaming Wu et al. Poster No. 144, November 17, 12:00 - 2:20 p.m. CEST
"An antisense molecule to HER3 sustains growth inhibitory effects in gefitinib resistant cells that are independent of MET overexpression," Zhengxing Qu et al. Poster No. 307, November 18, 12:00 - 2:20 p.m. CEST
Source: Enzon Pharmaceuticals, Inc.